Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update.

Literature DB >> 27927718

ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update.

Silvio Danese^1,2, Gionata Fiorino³, Tim Raine⁴, Marc Ferrante⁵, Karen Kemp⁶, Jaroslaw Kierkus⁷, Peter L Lakatos⁸, Gerassimos Mantzaris⁹, Janneke van der Woude¹⁰, Julian Panes¹¹, Laurent Peyrin-Biroulet¹².

Abstract

Mesh：

Substances：

Year: 2016 PMID： 27927718 DOI： 10.1093/ecco-jcc/jjw198

Source DB: PubMed Journal: J Crohns Colitis ISSN： 1873-9946 Impact factor: 9.071

Keyword Cloud
Cited

× No keyword cloud information.

53 in total

Review 1. Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction.

Authors: Ylenia Ingrasciotta; Paola M Cutroneo; Ilaria Marcianò; Thijs Giezen; Fabiola Atzeni; Gianluca Trifirò
Journal: Drug Saf Date: 2018-11 Impact factor: 5.606

2. Systematic literature review of the methodology for developing pharmacotherapeutic interchange guidelines and their implementation in hospitals and ambulatory care settings.

Authors: Maria Adrover-Rigo; Maria-Dolores Fraga-Fuentes; Francesc Puigventos-Latorre; Iciar Martinez-Lopez
Journal: Eur J Clin Pharmacol Date: 2018-10-19 Impact factor: 2.953

3. A SPECIAL MEETING REVIEW EDITION: Highlights in Biosimilars From the World Congress of Gastroenterology at ACG 2017: Introduction: A Review of Selected Presentations From the World Congress of Gastroenterology at ACG 2017 • October 13-18, 2017 • Orlando, FloridaSpecial Reporting on:• Biosimilars: What Are They and How Will They Change the Way We Practice?• Infliximab Assay Used in Clinical Practice Validated for Measuring SB2 Infliximab Biosimilar's Serum Drug and Anti-Drug Antibody Levels• Efficacy of Infliximab Biosimilar for Induction and Maintenance Therapy in Inflammatory Bowel Disease After Switch From Drug Originator: A Meta-Analysis• Long-Term Efficacy, Safety, and Immunogenicity Data From a Phase III Confirmatory Study Comparing GP2017, a Proposed Biosimilar, With Reference Adalimumab• Patient Perceptions Regarding the Use of Biosimilars in Inflammatory Bowel Disease• FDA Public Forum on BiosimilarsWith an Introduction and Expert Commentary by:Gary R. Lichtenstein, MDProfessor of MedicineDirector, Center for Inflammatory Bowel DiseaseUniversity of Pennsylvania Health SystemHospital of the University of PennsylvaniaPhiladelphia, Pennsylvania.

Authors:
Journal: Gastroenterol Hepatol (N Y) Date: 2017-12

Review 4. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.

Authors: Christopher Andrew Lamb; Nicholas A Kennedy; Tim Raine; Philip Anthony Hendy; Philip J Smith; Jimmy K Limdi; Bu'Hussain Hayee; Miranda C E Lomer; Gareth C Parkes; Christian Selinger; Kevin J Barrett; R Justin Davies; Cathy Bennett; Stuart Gittens; Malcolm G Dunlop; Omar Faiz; Aileen Fraser; Vikki Garrick; Paul D Johnston; Miles Parkes; Jeremy Sanderson; Helen Terry; Daniel R Gaya; Tariq H Iqbal; Stuart A Taylor; Melissa Smith; Matthew Brookes; Richard Hansen; A Barney Hawthorne
Journal: Gut Date: 2019-09-27 Impact factor: 23.059

Review 10. Mechanism-Based Treatment Strategies for IBD: Cytokines, Cell Adhesion Molecules, JAK Inhibitors, Gut Flora, and More.

Authors: Philipp Schreiner; Markus F Neurath; Siew C Ng; Emad M El-Omar; Ala I Sharara; Taku Kobayashi; Tadakazu Hisamatsu; Toshifumi Hibi; Gerhard Rogler
Journal: Inflamm Intest Dis Date: 2019-07-09

ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update.

Review 1. Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction.

2. Systematic literature review of the methodology for developing pharmacotherapeutic interchange guidelines and their implementation in hospitals and ambulatory care settings.

Review 4. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.

5. IBD: To switch or not to switch: that is the biosimilar question.

6. Introduction to Biosimilar Use in Patients With Inflammatory Bowel Disease.

7. Biosimilars for the Treatment of Inflammatory Bowel Disease.

8. The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries.

9. Changes in inflammatory bowel disease patients' perspectives on biosimilars: A follow-up survey.

Review 10. Mechanism-Based Treatment Strategies for IBD: Cytokines, Cell Adhesion Molecules, JAK Inhibitors, Gut Flora, and More.